Tamoxifen, megestrol acetate, and beta interferon in endometrial cancer.
22 patients with endometrial cancer were studied. Twelve (54.5%) between 45 and 66 years were treated for six days before surgery with 160 mg per os of Megestrol acetate administered twice daily plus Beta interferon 3,000,000 IU- on alternate days for a week, plus Tamoxifen--two cp of 10 mg daily for six days. Before and after surgery and associated medical therapies the steroid receptor values (ER and PgR) were checked. After treatment an average increase was observed of the ER (19 fmol/mg) and PgR (17 fmol/mg). Of the twelve patients one died of a stroke during the study (8.33%); five (41.67%) showed complete remission (CR); four (33.34%) a partial remission (PR) and two (16.67%) were not responders (NR).
Cardone
A
A
II University of Naples School of Medicine, Dept of Gynaecology and Obstetrics, Italy.
Tolino
A
A
Di Serio
C
C
Borruto Caracciolo
G
G
Caccavale
C
C
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000601:surgery / Q000648:ultrastructure; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage; D008535:Megestrol / Q000008:administration & dosage / Q000031:analogs & derivatives; D019290:Megestrol Acetate; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013629:Tamoxifen / Q000008:administration & dosage
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D016899:Interferon-beta; D008535:Megestrol; D019290:Megestrol Acetate